Harmony Biosciences (NASDAQ: HRMY)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-09 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.290 | 0.510 | 0.2200 | ||||
REV | 88.550M | 85.313M | -3.237M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Harmony Biosciences (NASDAQ: HRMY) through any online brokerage.
Other companies in Harmony Biosciences’s space includes: Sundial Growers (NASDAQ:SNDL), Reata Pharmaceuticals (NASDAQ:RETA), Supernus Pharmaceuticals (NASDAQ:SUPN), Roivant Sciences (NASDAQ:ROIV) and Axsome Therapeutics (NASDAQ:AXSM).
The latest price target for Harmony Biosciences (NASDAQ: HRMY) was reported by Cantor Fitzgerald on Thursday, April 14, 2022. The analyst firm set a price target for 63.00 expecting HRMY to rise to within 12 months (a possible 52.43% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Harmony Biosciences (NASDAQ: HRMY) is $41.33 last updated May 20, 2022, 8:00 PM UTC.
There are no upcoming dividends for Harmony Biosciences.
Harmony Biosciences’s Q2 earnings are confirmed for Tuesday, August 9, 2022.
There is no upcoming split for Harmony Biosciences.
Harmony Biosciences is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.